Astria Therapeutics (ATXS) said Thursday the final results of its phase 1b/2 clinical trial evaluating navenibart in hereditary angioedema patients showed strong efficacy and a favorable safety and tolerability profile.

Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling.

Conducted across 20 sites in six countries, the trial results showed a significant attack rate reduction, supporting both dosing regimens of every three months and every six months, the company said.

The phase 3 trial is progressing, with topline results expected in early 2027, Astria said.

Price: 12.48, Change: -0.15, Percent Change: -1.15